A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Proactive Management in Pediatric Subjects with Moderate to Severe Atopic Dermatitis

Efficacy And Safety ◽

Open Label ◽

Proactive Management ◽

Parallel Group Study ◽

A Phase II, Randomized, Open-Label, Parallel-Group Study to Evaluate the Efficacy and Safety of Autologous Dendritic Cell Vaccination (ADCV01) as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients

Case Medical Research ◽

10.31525/ct1-nct04115761 ◽

2019 ◽

Author(s):

Keyword(s):

Dendritic Cell ◽

Glioblastoma Multiforme ◽

Phase Ii ◽

Dendritic Cell Vaccination ◽

Efficacy And Safety ◽

Autologous Dendritic Cell ◽

Open Label ◽

Primary Glioblastoma ◽

Parallel Group Study ◽

A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome

Biomedical Journal ◽

10.1016/j.bj.2015.09.002 ◽

2016 ◽

Vol 39 (1) ◽

pp. 72-80 ◽

Cited By ~ 16

Author(s):

K. Girish ◽

K. Vikram Reddy ◽

Lakshmi V. Pandit ◽

H.P. Pundarikaksha ◽

R. Vijendra ◽

...

Keyword(s):

Alcohol Withdrawal ◽

Withdrawal Syndrome ◽

Alcohol Withdrawal Syndrome ◽

Efficacy And Safety ◽

Open Label ◽

Parallel Group Study ◽

26313 Efficacy and safety of dupilumab for up to 1 year in a phase 3 open-label extension (OLE) trial (LIBERTY AD PED-OLE) in adolescents with uncontrolled, moderate-to-severe atopic dermatitis (AD)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.408 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB97

Author(s):

Andrew Blauvelt ◽

Emma Guttman-Yassky ◽

Amy S. Paller ◽

Eric L. Simpson ◽

John Browning ◽

...

Keyword(s):

Atopic Dermatitis ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Open Label Extension

A multinational, multicenter, open-label, controlled, randomised, parallel group study to evaluate the efficacy and safety of EMD 121974 and gemcitabine or gemcitabine alone in patients with advanced, unresectable pancreatic cancer

http://isrctn.org/> ◽

10.1186/isrctn13413322 ◽

2013 ◽

Author(s):

Helmut Friess

Keyword(s):

Pancreatic Cancer ◽

Unresectable Pancreatic Cancer ◽

Efficacy And Safety ◽

Open Label ◽

Parallel Group Study ◽

A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment

British Journal of Dermatology ◽

10.1111/bjd.18384 ◽

2019 ◽

Vol 182 (4) ◽

pp. 869-879 ◽

Cited By ~ 6

Author(s):

K. Reich ◽

M. Augustin ◽

D. Thaçi ◽

A. Pinter ◽

A. Leutz ◽

...

Keyword(s):

Fumaric Acid ◽

Plaque Psoriasis ◽

Systemic Treatment ◽

Efficacy And Safety ◽

Open Label ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Parallel Group Study ◽

Parallel Group ◽

Acid Esters

Long-term efficacy and safety of incobotulinumtoxinA and conventional treatment of poststroke arm spasticity: a prospective, non-interventional, open-label, parallel-group study

BMJ Open ◽

10.1136/bmjopen-2015-009358 ◽

2015 ◽

Vol 5 (12) ◽

pp. e009358 ◽

Cited By ~ 12

Author(s):

Dirk Dressler ◽

Reinhard Rychlik ◽

Fabian Kreimendahl ◽

Nicole Schnur ◽

Judith Lambert-Baumann

Keyword(s):

Conventional Treatment ◽

Efficacy And Safety ◽

Open Label ◽

Term Efficacy ◽

Parallel Group Study ◽

A randomised open label parallel group study on evaluation of efficacy and safety of gemifloxacin versus cefpodoxime in chronic obstructive pulmonary disease patients.

International Journal of Pharma and Bio Sciences ◽

10.22376/ijpbs.2017.8.2.p324-331 ◽

2017 ◽

Vol 8 (2) ◽

Author(s):

RENU KA ◽

VASANTHI C ◽

DARLING CHELLATHAI

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

Open Label ◽

Obstructive Pulmonary Disease ◽

Parallel Group Study ◽

26880 Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged ≥6 to <12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.499 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB120

Author(s):

Michael J. Cork ◽

Diamant Thaçi ◽

Lawrence Eichenfield ◽

Peter D. Arkwright ◽

Zhen Chen ◽

...

Keyword(s):

Atopic Dermatitis ◽

Safety Data ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Term Efficacy ◽

Open Label Extension ◽

Extension Trial

Evaluation of the Efficacy and Safety of Lebrikizumab in Moderate to Severe Atopic Dermatitis

Case Medical Research ◽

10.31525/ct1-nct04178967 ◽

2019 ◽

Author(s):

Keyword(s):

Atopic Dermatitis ◽

Efficacy And Safety

Faculty Opinions recommendation of Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717995300.793478299 ◽

2013 ◽

Author(s):

Altaf Mangera

Keyword(s):

Low Dose ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Orally Disintegrating Tablet ◽

Parallel Group Study ◽